Pasar al contenido principal

ESTUDIO DEL MECANISMO DE ACCION DEL VCE-004.8, UN DERIVADO QUINONA DEL CANNABIDIOL. IMPLICACIONES TERAPEUTICAS EN ESCLEROSIS MULTIPLE.

SAF2017-87701-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE CORDOBA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Effect of oral VCE-004.8, a cannabidiol quinol derivative, on experimental autoimmune encephalomyelitis

  • Navarrete, Carmen
  • García, Adela
  • Palomares, Belén
  • Mestre, Leyre
  • Mecha, Miriam
  • Feliú, Ana
  • Garrido, Martín
  • Calzado, Marco A.
  • Bellido, María Luz
  • Guaza, Carmen
  • Muñoz, Eduardo
Trabajo presentado en el 28th Annual Symposium of the International Cannabinoid Research Society, celebrado en Leiden del 30 de junio al 5 de julio de 2018., Multiple Sclerosis (MS) is characterized by a combination of inflammatory and neurodegenerative processes that are dominantin different stages of the disease. Thus, immunosuppression is the goldstandard for the inflammatory stage and novel remyelination therapies are being pursued to restore lost function. While angiogenesis andblood-brain barrier(BBB)disruption are potentially negative in inflammatory phases, angiogenesis mediated by the stabilization of HIF-1αcould be beneficial for neuroprotection and axonal regeneration in remitting phases and progressive forms of the disease. Therefore, the development of complementary treatments aimed at axonal repair and remyelination and/or slowing the progression of the disease through neuroprotectionand axonal regeneration remain the most important objective in the clinical management of chronic progressive MS., Acknowledgements: Partially funded by MINECO grants SAF2014-53763-P and SAF2017-87701-R to EM., Peer reviewed